OCUP: ocuphire.com Price to Earnings Adjusted for Growth Rate

Ocuphire Pharma, Inc. (OCUP) is protected by patents for presbyopia and diabetes treatments under strict FDA oversight. The PEG ratio demonstrates value dynamics, where the 0.00 metric determines the parameter status. Long-term raw material supply agreements guarantee the stability of development. However, the business faces fierce competition for physician attention from medical behemoths.

OCUP Ocuphire Pharma, Inc. PEG Multiple (07/04/2022 - 10/24/2024)

Metric breakdowns and analytics for Ocuphire Corporation (OCUP)

- share price and consensus valuation forecast:

Price Performance Chart Ocuphire|OCUP - Analyst Consensus Forecast

- market capitalization information:

Market Value Ocuphire Pharma, Inc.|OCUP - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Net Asset Value per Share Ocuphire Pharma|OCUP - Book Capitalization|Market-to-Book Ratio ocuphire.com|OCUP - Aggregate Company Assets

- business debt structure and liquidity details:

- earnings and multiples data:

OCUP - Net Profit|Expected Net Income Ocuphire Pharma, Inc.|OCUP - P/E Multiple|Market Cap to Projected Earnings ocuphire.com|OCUP - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Ocuphire Corporation|OCUP - Operating profit EBITDA|Net earnings per one share for the last twelve months Ocuphire Pharma|OCUP - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ocuphire.com|OCUP - Earnings per share growth in current year|Net earnings per share change forecast for next year Ocuphire Pharma, Inc.

- issuer revenue and sales details:

OCUP - Revenue and Sales Volume|Company Future Revenue Ocuphire|OCUP - P/S Multiple|Forward P/S Multiple Ocuphire Pharma

General company analysis:OCUP (Ocuphire Pharma, Inc.)

The success of Ocuphire Pharma, Inc. (OCUP) depends on clinical trial results and the protection of intellectual property, which directly impacts future profit dynamics. The PEG ratio allows for a comparison of the current share price with expected business expansion: a value below one signals that the asset is undervalued relative to its potential, although it requires accounting for the risks of prolonged price stagnation.

Who Ocuphire Pharma, Inc. competes with